{"version":"1.0","provider_name":"South Africa Voice","provider_url":"https:\/\/southafricavoice.com","author_name":"South Africa Voice","author_url":"https:\/\/southafricavoice.com\/author\/southafricavoice01\/","title":"Adagio Therapeutics anuncia que o ADG20 (adintrevimabe) \u00e9 o primeiro anticorpo monoclonal a atingir a meta final principal com signific\u00e2ncia estat\u00edstica na profilaxia e tratamento pr\u00e9 e p\u00f3s-exposi\u00e7\u00e3o \u00e0 COVID-19, e que pretende solicitar autoriza\u00e7\u00e3o de uso de emerg\u00eancia nos EUA - South Africa Voice","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"SAYn3EAmet\"><a href=\"https:\/\/southafricavoice.com\/adagio-therapeutics-anuncia-que-o-adg20-adintrevimabe-e-o-primeiro-anticorpo-monoclonal-a-atingir-a-meta-final-principal-com-significancia-estatistica-na-profilaxia-e-tratamento-pre-e-pos-exposicao\/\">Adagio Therapeutics anuncia que o ADG20 (adintrevimabe) \u00e9 o primeiro anticorpo monoclonal a atingir a meta final principal com signific\u00e2ncia estat\u00edstica na profilaxia e tratamento pr\u00e9 e p\u00f3s-exposi\u00e7\u00e3o \u00e0 COVID-19, e que pretende solicitar autoriza\u00e7\u00e3o de uso de emerg\u00eancia nos EUA<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/southafricavoice.com\/adagio-therapeutics-anuncia-que-o-adg20-adintrevimabe-e-o-primeiro-anticorpo-monoclonal-a-atingir-a-meta-final-principal-com-significancia-estatistica-na-profilaxia-e-tratamento-pre-e-pos-exposicao\/embed\/#?secret=SAYn3EAmet\" width=\"600\" height=\"338\" title=\"&#8220;Adagio Therapeutics anuncia que o ADG20 (adintrevimabe) \u00e9 o primeiro anticorpo monoclonal a atingir a meta final principal com signific\u00e2ncia estat\u00edstica na profilaxia e tratamento pr\u00e9 e p\u00f3s-exposi\u00e7\u00e3o \u00e0 COVID-19, e que pretende solicitar autoriza\u00e7\u00e3o de uso de emerg\u00eancia nos EUA&#8221; &#8212; South Africa Voice\" data-secret=\"SAYn3EAmet\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"O risco de COVID-19 sintom\u00e1tico foi reduzido em 71% em compara\u00e7\u00e3o com placebo na profilaxia pr\u00e9-exposi\u00e7\u00e3o e 75% em compara\u00e7\u00e3o com placebo na profilaxia p\u00f3s-exposi\u00e7\u00e3o O risco de hospitaliza\u00e7\u00e3o ou morte dos participantes com COVID-19 leve a moderada foi reduzido em 66% em compara\u00e7\u00e3o com o placebo na popula\u00e7\u00e3o de an\u00e1lise de efic\u00e1cia prim\u00e1ria e [\u2026]"}